SC
VKTX icon

Sculptor Capital’s Viking Therapeutics VKTX Stock Holding History

Sculptor Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-174,700
Closed -$1.4M – 304
2019
Q4 		$1.4M Hold
174,700
– – 0.01% 192
2019
Q3 		$1.2M Sell
174,700
-262,400
-60% -$1.95M 0.01% 218
2019
Q2 		$3.63M Hold
437,100
– – 0.02% 142
2019
Q1 		$4.34M Buy
+437,100
New +$3.66M 0.03% 104

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Sculptor Capital's VKTX Position: Q1 2020 in Review

Sculptor Capital sold out of Viking Therapeutics (VKTX) in Q1 2020, closing a stake of 173,500 shares — an estimated $1.39M sold.

Sculptor Capital first reported a position in VKTX in Q1 2019 and held it in 4 quarters. The position peaked at $4.33M in Q1 2019. 137 funds tracked by Wall St. Rank hold VKTX as of Q1 2020.

  • Sculptor Capital reported no remaining Viking Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Sculptor Capital sold 173,500 Viking Therapeutics shares in Q1 2020, an estimated $1.39M.
  • Sculptor Capital first reported a position in Viking Therapeutics in Q1 2019 and held it in 4 quarters.
  • Sculptor Capital's Viking Therapeutics position peaked at $4.33M in Q1 2019.
  • 137 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2020.

Based on Sculptor Capital's 13F filing for Q1 2020, filed 14 May 2020.